Anna María Geretti

机构：University of Rome Tor Vergata, Royal Free London NHS Foundation Trust, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Center for Prevention and Treatment of Infections · ORCID：0000-0002-3670-6588

发表论文 360 篇 · 总被引 13366 次 · h-index 59

代表论文

• Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process (2025 · The Lancet HIV · 被引 10)
• Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions (2025 · Open Forum Infectious Diseases · 被引 10)
• Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case–control study (2025 · The Lancet Global Health · 被引 4)
• Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection (2025 · Antimicrobial Agents and Chemotherapy · 被引 1)
• Real-world Prevalence of Nonintegrase INSTI Resistance-Associated Mutations and Virological Outcomes in People Who Have Recently Acquired HIV-1 in the United Kingdom (2025 · The Journal of Infectious Diseases · 被引 1)
• COVID-19 and influenza vaccination among adults stably engaged in HIV care (2025 · Vaccine X · 被引 1)